Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Just In
Biden orders additional 500 troops to assist western NC amid crisis
Just In
Help Helene victims: Click to give money, give blood, donate goods or volunteer â¤ï¸ Here's your guide to help our western NC neighbors
Program
After the race on WRAL: Mitchell County businesses face long road to recovery after Helene. How owners are coming together to rebuild a community
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
113.95
+0.18 (+0.16%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis Ag ADR
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
May 01, 2024
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
April 29, 2024
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds...
Via
Benzinga
Exposures
Product Safety
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
April 29, 2024
The company is projected to bring in increasing sales through at least 2029.
Via
Investor's Business Daily
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
April 28, 2024
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for...
Via
Talk Markets
Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise
April 23, 2024
Shares have risen markedly over the past two days and gained again Tuesday.
Via
Investor's Business Daily
Looking At Novartis's Recent Unusual Options Activity
April 11, 2024
Via
Benzinga
What's Going On With Pfizer Stock On Thursday?
April 25, 2024
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Via
Investor's Business Daily
Why Novartis Stock Topped the Market on Tuesday
April 23, 2024
A double beat on the latest quarterly results and raised guidance made investors happy.
Via
The Motley Fool
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
April 23, 2024
Discover Novartis' FDA approval for Lutathera in pediatric patients with GEP-NETs, marking a pivotal milestone in treating this rare cancer. Explore its efficacy in combating SSTR+ tumors, backed by...
Via
Benzinga
Exposures
Product Safety
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024
April 23, 2024
NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
April 23, 2024
Stocks surged as weak economic data raised hopes for Fed rate cut. S&P 500 up 1.2%, Nasdaq 100 up 1.5%, Dow Jones up 0.6%. Spotify shares jump 17% on earnings.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
April 23, 2024
NVS earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
April 23, 2024
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth.
Via
Benzinga
Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback'
April 23, 2024
The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies that fueled much of the market’s upside since 2023. Index futures rose...
Via
Benzinga
Topics
Bonds
Exposures
Debt Markets
Top Analyst Reports For Novartis, American Express & ConocoPhillips
April 22, 2024
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).
Via
Talk Markets
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
April 19, 2024
AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically."
Via
Investor's Business Daily
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.
Via
Benzinga
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
April 19, 2024
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel
Via
Benzinga
Exposures
Product Safety
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
April 17, 2024
Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed.
Via
Benzinga
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
April 17, 2024
These income stocks look like good options at current levels.
Via
The Motley Fool
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
April 16, 2024
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.
Via
Benzinga
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
April 14, 2024
Think globally with this high-yielding ETF.
Via
The Motley Fool
Topics
ETFs
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
April 11, 2024
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth...
Via
Benzinga
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
April 11, 2024
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
Via
Investor's Business Daily
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
April 10, 2024
Alpine Immune Sciences explores strategic options, potentially selling amid interest from buyers. The Seattle-based firm, with soaring stock up over 400%, evaluates various possibilities.
Via
Benzinga
SOUN Stock Alert: The $150 Million Reason SoundHound AI Is Down Today
April 10, 2024
SoundHound AI stock is falling on Wednesday as investors in SOUN are worried about the company's plans for a secondary offering.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Jack Ma Is Giving Alibaba (BABA) Stock a Big Boost
April 10, 2024
Alibaba stock is up on Wednesday as investors in BABA react to positive comments from cofounder Jack Ma concerning its leadership team.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.